– USA, CA – Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the appointment of Dr. Jane Tiller (MBChB, FRCPsych) to its board of directors.
“We are thrilled to further strengthen the deep expertise of our Board with the addition of Dr. Tiller. Jane brings knowledge across multiple therapeutic areas including neuroscience, and a deep understanding and successful track record in strategy and execution in global clinical development and medical affairs,” said CEO, Kevin Lind. “These attributes will be invaluable as we advance and expand our robust pipeline and continue to build a world-class team.”
About Dr. Jane Tiller
Dr. Tiller currently serves as CMO of Neumora Therapeutics, a position she has held since Neumora acquired BlackThorn Therapeutics, where she had served as CMO. Before BlackThorn, Dr. Tiller was Head of Medical European Markets, Australia and Canada at Bristol-Myers Squibb, where she oversaw all medical functions for her territories. During her tenure at BMS, Dr. Tiller also served as VP of Global Medical for neuroscience, virology, and immunoscience, and as VP, Full Development Gamma Secretase for BMS’ Alzheimer’s program. Previously, she held positions of increasing responsibility at Cephalon, including as VP, Clinical Research, CNS/Pain, where she was responsible for all clinical development activities of programs for schizophrenia, bipolar disorder, anxiety, and sleep disorders. Before joining the industry, Dr. Tiller was Clinical Director at the Maudsley Hospital, London, a Consultant Psychiatrist, and honorary Senior Lecturer.
Dr. Tiller received her medical degree from the Glasgow University Medical School, an M.B.A. from Drexel University, and an MPhil from the University of Pennsylvania.
About Longboard Pharmaceuticals
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors. Longboard’s small molecule product candidates are based on more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting 5-HT2c receptor superagonist, with negligible observed impact on 5-HT2b and 5-HT2a receptor subtypes, in development for the potential treatment of seizures associated with developmental and epileptic encephalopathies. Longboard is also evaluating LP143, a centrally acting, full CB2 receptor agonist, in development for the potential treatment of neurodegenerative diseases associated with neuroinflammation caused by microglial activation, and LP659, a centrally acting, S1P receptor subtypes 1 and 5 modulator, in development for the potential treatment of central nervous system neuroinflammatory diseases.
For more information: https://www.longboardpharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.